Top

Cardiovascular Diabetology

Published in:

Open Access 01-12-2016 | Original investigation

Apolipoprotein E gene polymorphism and risk of type 2 diabetes and cardiovascular disease

Authors: Dalia El-Lebedy, Hala M. Raslan, Asmaa M. Mohammed

Published in: Cardiovascular Diabetology | Issue 1/2016

Abstract

Background

Lipoprotein-related mechanisms have been associated with damage to the cardiovascular system in diabetic patients. Apolipoprotein E gene which affects the clearance of lipoproteins and consequently the lipid profile in our body is one of the most studied candidate genes and recently has been reported to be associated with T2DM and CAD. In this work, we studied the association of apoE gene polymorphism with T2DM and CVD and its effect on plasma lipids profile.

Methods

Our study was conducted on 284 subjects categorized into 100 patients with T2DM, 100 patients with T2DM complicated with CVD and 84 normal control subjects. ApoE gene polymorphism was genotyped by real-time PCR using TaqMan^® SNP Genotyping Assay.

Results

ApoE E3/E3 genotype was the most common in our subjects. The frequencies of E3/E4 genotype and ε4 allele were increased in both T2DM patients and CVD patients as compared with controls, but were significant only in CVD patients (p = 0.004 and 0.007, respectively). Diabetic patients who carried E3/E4 genotype were at 2.4-fold increased risk to develop CVD (95 % CI 1.14–5.19, P = 0.02) and the ε4 allele associated with 2.23-fold higher CVD risk (95 % CI 1.09–4.59, P = 0.02). After adjustment for other established risk factors, E3/E4 genotype was an independent risk factor for CVD (OR = 2.3, p = 0.009) but not for T2DM (OR = 1.7, p = 0.28), while ε4 allele was an independent risk factor for both T2DM (OR = 2.2, p = 0.04) and CVD (OR = 3.0, p = 0.018) with 5.9-fold increased risk to develop CVD in T2DM patients (p = 0.019). E3/E4 genotype associated with significantly higher levels of TC and non HDL-C in all groups and with significantly higher levels of LDL-C in both T2DM and CVD patients.

Conclusions

ApoE gene polymorphisms associate with CVD and affect the lipid profile. The ε4 allele is an independent risk factor for both T2DM and CVD. Further genetic studies to add information beyond the traditional cardiovascular risk factors in T2DM and to identify risk genotypes will help in early prediction and identification of at risk patients.

King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414–31.CrossRefPubMed

International Diabetes Federation (IDF). Diabetes Atlas, 2nd edn. Brussels: International Diabetes Federation. 2003.

International Diabetes Federation (IDF). Diabetes Atlas, 5th edn. Brussels: International Diabetes Federation. 2013, update.

Lorber D. Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2014;7:169–83.PubMedCentralCrossRefPubMed

http://www.idf.org/webdata/docs/background_cairo.pdf. Accessed 15 Sep 2015.

Horejsí B, Ceska R. Apolipoproteins and atherosclerosis. Apolipoprotein E and apolipoprotein (a) as candidate genes of premature development of atherosclerosis. Physiol Res. 2000;49(Suppl 1):S63–9.PubMed

Jenkins AJ, Rowley KG, Lyons TJ, Best JD, Hill MA, Klein RL. Lipoproteins and diabetic microvascular complications. Curr Pharm Des. 2004;10:3395–418.CrossRefPubMed

Ferreira CN, Carvalho MG, Fernandes AP, Lima LM, Loures-Valle AA, Dantas J, Janka Z, Palotás A. Sousa MO. Comparative study of apolipoprotein-E polymorphism and plasma lipid levels in dyslipidemic and symptomatic subjects, and their implication in cardio/cerebro-vascular disorders Neurochem Int. 2010;56(1):177–82.

Grundy SM. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov. 2006;5:295–309.CrossRefPubMed

10.

Singh PP, Singh M, Mastana SS. APOE distribution in world populations with new data from India and the UK. Ann Hum Biol. 2006;33:279–308.CrossRefPubMed

11.

Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol. 2002;155:487–95.CrossRefPubMed

12.

Guang-da X, You-ying L, Zhi-song C, Yu-sheng H, Xiang-jiu Y. Apolipoprotein ε4 allele is predictor of coronary artery disease death in elderly patients with type 2 diabetes mellitus. Atherosclerosis. 2004;175:77–81.CrossRefPubMed

13.

Knouff C, Hinsdale ME, Mezdour H, Altenburg MK, Watanabe M, Quarfordt SH, Sullivan PM, Maeda N. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest. 1999;103:1579–86.PubMedCentralCrossRefPubMed

14.

Chaudhary R, Likidlilid A, Thavatchai Peerapatdit T, Damras Tresukosol D, Srisuma S, Ratanamaneechat S, Sriratanasathavorn C. Apolipoprotein E gene polymorphism: effects on plasma lipids and risk of type 2 diabetes and coronary artery disease. Cardiovasc Diabetol. 2012;11:36.PubMedCentralCrossRefPubMed

15.

Jellinger PS, Dickey RA, Ganda OP, Mehta AE, Nguyen TT, Rodbard HW, Seibel JA, Shepherd MD, Smith DA, AACE Lipid Guidelines Committee. The American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of dyslipidemia and prevention of atherogenesis. Endocr Pract. 2000;6(2):162–213.PubMed

16.

American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Suppl. 1):S81–90.CrossRef

17.

Hermans MP, Sacks FM, Ahn SA, Rousseau MF. Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: discriminant ratio and unbiased equivalence. Cardiovasc Diabetol. 2011;10:20.PubMedCentralCrossRefPubMed

18.

Mahley RW, Rall SC. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507–37.CrossRefPubMed

19.

Mendes-Lana A, Pena GG, Freitas SN, Lima AA, Nicolato RL, Nascimento-Neto RM, Machado-Coelho GL, Freitas RN. Apolipoprotein E polymorphism in Brazilian dyslipidemic individuals: Ouro Preto study. Braz J Med Biol Res. 2007;40(1):49–56.CrossRefPubMed

20.

Laakso M, Kesäniemi A, Kervinen K, Jauhiainen M, Pyörälä K. Relation of coronary heart disease and apolipoprotein E phenotype in patients with non-insulin dependent diabetes. BMJ. 1991;303(6811):1159–62.PubMedCentralCrossRefPubMed

21.

Ukkola O, Kervinen K, Salmela PI, von Dickhoff K, Laakso M, Kesäniemi YA. Apolipoprotein E phenotype is related to macro- and microangiopathy in patients with non-insulin-dependent diabetes mellitus. Atherosclerosis. 1993;101(1):9–15.CrossRefPubMed

22.

Boemi M, Sirolla C, Amadio L, Fumelli P, Pometta D, James RW. Apolipoprotein E polymorphism as a risk factor for vascular disease in diabetic patients. Diabetes Care. 1995;18(4):504–8.CrossRefPubMed

23.

Corbo RM, Vilardo T, Ruggeri M, Gemma AT, Scacchi R. Apolipoprotein E genotype and plasma levels in coronary artery disease. A case-control study in the Italian population. Clin Biochem. 1999;32:217–22.CrossRefPubMed

24.

Kolovou G, Yiannakouris N, Hatzivassiliou M, Malakos J, Daskalova D, Hatzigeorgiou G, Cariolou MA, Cokkinos DV. Association of apolipoprotein E polymorphism with myocardial infarction in Greek patients with coronary artery disease. Curr Med Res Opin. 2002;18(3):118–24.CrossRefPubMed

25.

Kolovou GD, Daskalova DCh, Hatzivassiliou M, Yiannakouris N, Pilatis ND, Elisaf M, Mikhailidis DP, Cariolou MA, Cokkinos DV. The epsilon 2 and 4 alleles of apolipoprotein E and ischemic vascular events in the Greek population—implications for the interpretation of similar studies. Angiology. 2003;54(1):51–8.CrossRefPubMed

26.

Vaisi-Raygani A, Rahimi Z, Nomani H, Tavilani H, Pourmotabbed T. The presence of apolipoprotein epsilon4 and epsilon2 alleles augments the risk of coronary artery disease in type 2 diabetic patients. Clin Biochem. 2007;40(15):1150–6.CrossRefPubMed

27.

Attila G, Acarturk E, Eskandari G, Akpinar O, Tuli A, Kanadas IM, Kayrin L. Effects of apolipoprotein E genotypes and other risk factors on the development of coronary artery disease in Southern Turkey. Clin Chim Acta. 2001;312(1–2):191–6.CrossRefPubMed

28.

Kumar P, Luthra K, Dwivedi M, Behl VK, Pandey RM, Misra A. Apolipoprotein E gene polymorphisms in patients with premature myocardial infarction: a case controlled study in Asian Indians in North India. Ann Clin Biochem. 2003;40:382–7.CrossRefPubMed

29.

Eichner JE, Kuller LH, Orchard TJ, Grandits GA, McCallum LM, Ferrell RE, Neaton JD. Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. Am J Cardiol. 1993;71:160–5.CrossRefPubMed

30.

Van Bockxmeer FM, Mamotte CD. Apolipoprotein epsilon4 homozygosity in young men with coronary heart disease. Lancet. 1992;340:879–80.CrossRefPubMed

31.

Yan S, Zhou X, Lin Q, Song Y. Association of polymorphism of apolipoprotein E gene with coronary heart disease in Han Chinese. Chin Med J (Engl). 1999;112:224–7.PubMed

32.

Chaaba R, Attia N, Hammami S, Smaoui M, Ben Hamda K, Mahjoub S, Hammami M. Association between apolipoprotein E polymorphism, lipids, and coronary artery disease in Tunisian type 2 diabetes. J Clin Lipidol. 2008;2:360–4.CrossRefPubMed

33.

Halim EF, Reda AA, Hendi AA, Zaki SA, Essa ES, Khalifa AS. Apolipoprotein E gene variants as a risk factor for coronary artery disease in type 2 diabetic Egyptian patients. Egypt J Immunol. 2012;19(1):1–10.PubMed

34.

Afroze D, Yousuf A, Tramboo NA, Shah ZA, Ahmad A. ApoE gene polymorphism and its relationship with coronary artery disease in ethnic Kashmiri population. Clin Exp Med. 2015; 1–6.

35.

Zhu H, Xue H, Wang HT, Ma YM, Liu J, Chen YD. The association of apolipoprotein E (APOE) gene polymorphisms with atherosclerosis susceptibility: a meta-analysis. Minerva Cardioangiol. 2015 [Epub ahead of print].

36.

Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002;23:599–622.CrossRefPubMed

37.

Tosukhowong P, Sangwatanaroj S, Jatuporn S, Prapunwattana P, Saengsiri A, Rattanapruks S, Srimahachota S, Udayachalerm W, Tangkijvanich P. The correlation between markers of oxidative stress and risk factors of coronary artery disease in Thai patients. Clin Hemorheol Microcirc. 2003;29:321–9.PubMed

38.

Fiorentino TV, Prioletta A, Zuo P, Folli F. Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. Curr Pharm Des. 2013;19(32):5695–703.CrossRefPubMed

39.

Mohammedi K, Bellili-Muñoz N, Marklund SL, Driss F, Le Nagard H, Patente TA, Fumeron F, Roussel R, Hadjadj S, Marre M, Velho G. Plasma extracellular superoxide dismutase concentration, allelic variations in the SOD3 gene and risk of myocardial infarction and all-cause mortality in people with type 1 and type 2 diabetes. Cardiovasc Diabetol. 2015;14:845.PubMedCentralCrossRefPubMed

40.

Hedrick CC, Thorpe SR, Fu MX. Glycation impairs high-density lipoprotein function. Diabetologia. 2000;43:312–20.CrossRefPubMed

41.

Ferretti G, Bacchetti T, Marchionni C, Caldarelli L, Curatola G. Effect of glycation of high density lipoproteins on their physiochemical properties and on paraoxonase activity. Acta Diabetol. 2001;38:163–9.CrossRefPubMed

42.

Leviev I, Kalix B, Brulhart-Meynet MC, James RW. The paraoxonase PON1 promoter polymorphism C(−107)T is associated with increased serum glucose concentrations in non-diabetic patients. Diabetologia. 2001;44:1177–83.CrossRefPubMed

43.

Senti M, Tomas M, Fito M. Anti oxidant paraoxonase-1 activity in the metabolic syndrome. J Clin Endocrinol Metab. 2003;88:5422–6.CrossRefPubMed

44.

Bansal S, Chawla D, Siddarth M, Banerjee BD, Madhu SV, Tripathi AK. A study on serum advanced glycation end products and its association with oxidative stress and paraoxonase activity in type 2 diabetic patients with vascular complications. Clin Biochem. 2013;46(1–2):109–14.CrossRefPubMed

45.

Getz GS, Wool GD, Reardon CA. Biological properties of apolipoprotein A-I mimetic peptides. Curr Atheroscler Rep. 2010;12(2):96–104.PubMedCentralCrossRefPubMed

46.

Shen Y, Ding FH, Sun J, Pu LJ, Zhang RY, Zhang Q, Chen QJ, Shen WF, Lu L. Association of elevated apoA-I glycation and reduced HDL-associated paraoxonase1, 3 activity, and their interaction with angiographic severity of coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2015;14:52.PubMedCentralCrossRefPubMed

47.

Jinnouchi H, Morita K, Tanaka T, Kajiwara A, Kawata Y, Oniki K, Saruwatari J, Nakagawa K, Otake K, Ogata Y, Yoshida A, Hokimoto S, Ogawa H. Interactive effects of a common γ-glutamyltransferase-1 variant and low high-density lipoprotein-cholesterol on diabetic macro- and micro-angiopathy. Cardiovasc Diabetol. 2015;14:49.PubMedCentralCrossRefPubMed

48.

Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ, Robbins DC, Howard BV. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care. 2003;26(1):16–23.CrossRefPubMed

49.

Singh PP, Singh M, Bhatnagar DP, Kaur TP, Gaur SK. Apolipoprotein E polymorphism and its relation to plasma lipids in coronary heart disease. Indian J Med Sci. 2008;62:105–12.CrossRefPubMed

50.

Inamdar PA, Kelkar SM, Devasagayam TP, Bapat MM. Apolipoprotein E polymorphism in non-insulin-dependent diabetics of Mumbai, India and its effect on plasma lipids and lipoproteins. Diabetes Res Clin Pract. 2000;47:217–23.CrossRefPubMed

51.

Gomez-Coronado D, Alvarez JJ, Entrala A, Olmos JM, Herrera E, Lasuncion MA. Apolipoprotein E polymorphism in men and women from a Spanish population: allele frequencies and influence on plasma lipids and apolipoproteins. Atherosclerosis. 1999;147:167–76.CrossRefPubMed

Title: Apolipoprotein E gene polymorphism and risk of type 2 diabetes and cardiovascular disease
Authors: Dalia El-Lebedy
Hala M. Raslan
Asmaa M. Mohammed
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Cardiovascular Diabetology / Issue 1/2016
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/s12933-016-0329-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study

Different relationship between ANGPTL3 and HDL components in female non-diabetic subjects and type-2 diabetic patients

Metformin improves the angiogenic potential of human CD34+ cells co-incident with downregulating CXCL10 and TIMP1 gene expression and increasing VEGFA under hyperglycemia and hypoxia within a therapeutic window for myocardial infarction

The EMPA-REG outcome study: critical appraisal and potential clinical implications

Transcriptomic alterations in the heart of non-obese type 2 diabetic Goto-Kakizaki rats

Use of imaging and clinical data to screen for cardiovascular disease in asymptomatic diabetics

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials